Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Northfield Labs Reports Verified Data From Troubled Phase III PolyHeme Study

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Northfield Laboratories is moving ahead with plans to file a BLA for its investigational red blood cell substitute PolyHeme, despite protocol violations that triggered a data verification process and a planned safety analysis to gain insight on myocardial infarction data

You may also be interested in...

FDA rejects Northfield Labs PolyHeme BLA

FDA sends "refuse-to-file" letter to Northfield Labs in November regarding the firm's PolyHeme BLA submission. Northfield submitted a BLA for the polymerized blood substitute Aug. 28. According to the firm, the agency is "seeking additional information before accepting the application for filing." Northfield will be discussing the necessary steps with FDA "over the next few months"

Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s

Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.

Alzheimer’s, BRAIN Initiative Highlighted In $30 Billion NIH Budget Proposal

President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts